-
1
-
-
0037192551
-
Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: A randomized trial
-
Meynard, J. L., Vray, M., Morand-Joubert, L., Race, E., Descamps, D., Peytavin, G. et al. (2000). Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS 16, 727-36.
-
(2000)
AIDS
, vol.16
, pp. 727-736
-
-
Meynard, J.L.1
Vray, M.2
Morand-Joubert, L.3
Race, E.4
Descamps, D.5
Peytavin, G.6
-
2
-
-
0033606540
-
Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial
-
Durant, J., Clevenbergh, P., Halfon, P., Delgiudice, P., Porsin, S., Simonet, P. et al. (1999). Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 353, 2195-9.
-
(1999)
Lancet
, vol.353
, pp. 2195-2199
-
-
Durant, J.1
Clevenbergh, P.2
Halfon, P.3
Delgiudice, P.4
Porsin, S.5
Simonet, P.6
-
3
-
-
0033920318
-
A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy
-
CPCRA 046 Study Team for the Terry Beim Community Programs for Clinical Research on AIDS
-
Baxter, J. D., Mayers, D. L., Wentworth, D. N., Neaton, J. D., Hoover, M. L., Winters, M. A. et al. (2000). A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beim Community Programs for Clinical Research on AIDS. AIDS 14, F83-93.
-
(2000)
AIDS
, vol.14
-
-
Baxter, J.D.1
Mayers, D.L.2
Wentworth, D.N.3
Neaton, J.D.4
Hoover, M.L.5
Winters, M.A.6
-
4
-
-
0037040360
-
A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy
-
Cohen, C. J., Hunt, S., Sension, M., Farthing, C., Conant, M., Jacobson, S. et al. (2000). A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 16, 579-88.
-
(2000)
AIDS
, vol.16
, pp. 579-588
-
-
Cohen, C.J.1
Hunt, S.2
Sension, M.3
Farthing, C.4
Conant, M.5
Jacobson, S.6
-
5
-
-
0037169170
-
Clinical utility of HIV-1 genotyping and expert advice: The Havana trial
-
Tural, C., Ruiz, L., Holtzer, C., Schapiro, J., Viciana, P., Gonzalez, J. et al. (2000). Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 16, 209-18.
-
(2000)
AIDS
, vol.16
, pp. 209-218
-
-
Tural, C.1
Ruiz, L.2
Holtzer, C.3
Schapiro, J.4
Viciana, P.5
Gonzalez, J.6
-
6
-
-
0033862761
-
Clinical manifestations and management of antiretroviral nucleoside analogue related mitochondrial toxicity
-
Moyle, G. (2000). Clinical manifestations and management of antiretroviral nucleoside analogue related mitochondrial toxicity. Clinical Therapeutics 22, 911-36.
-
(2000)
Clinical Therapeutics
, vol.22
, pp. 911-936
-
-
Moyle, G.1
-
7
-
-
0036066762
-
The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults
-
Kilby, J. M., Lalezari, J. P., Eron, J. J., Carlson, M., Cohen, C., Arduino, R. C. et al. (2002). The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Pesearch and Human Retroviruses 18, 685-93.
-
(2002)
AIDS Pesearch and Human Retroviruses
, vol.18
, pp. 685-693
-
-
Kilby, J.M.1
Lalezari, J.P.2
Eron, J.J.3
Carlson, M.4
Cohen, C.5
Arduino, R.C.6
-
8
-
-
0037471311
-
A Phase II clinical study of the long-term safety and antiviral activity of enfuvirtide (T-20) based antiretroviral therapy
-
in press
-
Lalezari, J. P., Eron, J. J., Carlson, M., Cohen, C., DeJesus, E., Arduino, R. C. et al. (2003). A Phase II clinical study of the long-term safety and antiviral activity of enfuvirtide (T-20) based antiretroviral therapy. AIDS, in press.
-
(2003)
AIDS
-
-
Lalezari, J.P.1
Eron, J.J.2
Carlson, M.3
Cohen, C.4
DeJesus, E.5
Arduino, R.C.6
-
9
-
-
0013425084
-
A week 48 assessment of a randomized, controlled, open-label phase II trial (T20-206) evaluating three doses of T-20 in P1-experienced, NNRTI-naïve patients infected with HIV-1
-
Program and Abstracts of the Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA, 2002. Abstract 418-W. Foundation for Retrovirology and Human Health, Alexandria, VA, USA
-
Lalezari, J., DeJesus, E., Northfelt, D., Richmond, G., Delehanty, J., DeMasi, R. et al. (2002). A week 48 assessment of a randomized, controlled, open-label phase II trial (T20-206) evaluating three doses of T-20 in P1-experienced, NNRTI-naïve patients infected with HIV-1. In Program and Abstracts of the Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA, 2002. Abstract 418-W. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
-
(2002)
-
-
Lalezari, J.1
DeJesus, E.2
Northfelt, D.3
Richmond, G.4
Delehanty, J.5
DeMasi, R.6
-
10
-
-
0013382197
-
48-week assessment of high strength T-20 in multi-class experienced patients
-
Program and Abstracts of the Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA, 2002. Abstract 417-W. Foundation for Retrovirology and Human Health, Alexandria, VA, USA
-
Wheat, L. J., Lalezari, J., Kilby, M., Wheeler, D., Salgo, M., DeMasi, R. et al. (2002). 48-week assessment of high strength T-20 in multi-class experienced patients. In Program and Abstracts of the Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA, 2002. Abstract 417-W. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
-
(2002)
-
-
Wheat, L.J.1
Lalezari, J.2
Kilby, M.3
Wheeler, D.4
Salgo, M.5
DeMasi, R.6
-
11
-
-
0003209749
-
Enfuvirtide (T-20) in combination with an optimized background (OB) regimen vs. OB alone in patients with prior experience or resistance to each of the 3 approved antiretrovirals (ARVs) in North America and Brazil (TORO 1)
-
Program and Abstracts of the Fourteenth International AIDS Conference, Barcelona, Spain, 2002. Abstract LBOr19B. IAS International AIDS Society, Stockholm, Sweden
-
Henry, K., Lalezari, J., O'Hearn, M., Trottier, B., Montaner, J., Piliero, P. et al. (2002). Enfuvirtide (T-20) in combination with an optimized background (OB) regimen vs. OB alone in patients with prior experience or resistance to each of the 3 approved antiretrovirals (ARVs) in North America and Brazil (TORO 1). In Program and Abstracts of the Fourteenth International AIDS Conference, Barcelona, Spain, 2002. Abstract LBOr19B. IAS International AIDS Society, Stockholm, Sweden.
-
(2002)
-
-
Henry, K.1
Lalezari, J.2
O'Hearn, M.3
Trottier, B.4
Montaner, J.5
Piliero, P.6
-
12
-
-
0003245253
-
Enfuvirtide (T-20) in combination with an optimized background (OB) regimen vs. OB alone in patients with prior experience or resistance to each of the 3 approved antiretrovirals (ARVs) in Europe and Australia (TORO 2)
-
Program and Abstracts of the Fourteenth International AIDS Conference, Barcelona, Spain, 2002. Abstract LBOr19A. IAS International AIDS Society, Stockholm, Sweden
-
Clotet, B., Lazzarin, A., Cooper, D., Reynes, J., Arasteh, K., Nelson, M. et al. (2002). Enfuvirtide (T-20) in combination with an optimized background (OB) regimen vs. OB alone in patients with prior experience or resistance to each of the 3 approved antiretrovirals (ARVs) in Europe and Australia (TORO 2). In Program and Abstracts of the Fourteenth International AIDS Conference, Barcelona, Spain, 2002. Abstract LBOr19A. IAS International AIDS Society, Stockholm, Sweden.
-
(2002)
-
-
Clotet, B.1
Lazzarin, A.2
Cooper, D.3
Reynes, J.4
Arasteh, K.5
Nelson, M.6
-
13
-
-
0013428074
-
Patient survey on injection of enfuvirtide (T-20): Ease of use and impact on activities
-
Program and Abstracts of the Fourteenth International AIDS Conference, Barcelona, Spain, 2002. Abstract TuPeB4480. IAS International AIDS Society, Stockholm, Sweden
-
Green, J., Salgo, M. P. & Delehanty, J. (2002). Patient survey on injection of enfuvirtide (T-20): ease of use and impact on activities. In Program and Abstracts of the Fourteenth International AIDS Conference, Barcelona, Spain, 2002. Abstract TuPeB4480. IAS International AIDS Society, Stockholm, Sweden.
-
(2002)
-
-
Green, J.1
Salgo, M.P.2
Delehanty, J.3
-
14
-
-
0028841633
-
Predicting diabetic control from competence, adherence, adjustment, and psychopathology 1629-1636
-
Daviss, W. B., Coon, H., Whitehead, P., Ryan, K., Burkley, M. & McMahon, W. (1995). Predicting diabetic control from competence, adherence, adjustment, and psychopathology. Journal of the American Academy of Child and Adolescent Psychiatry 34, 1629-36.
-
(1995)
Journal of the American Academy of Child and Adolescent Psychiatry
, vol.34
, pp. 1629-1636
-
-
Daviss, W.B.1
Coon, H.2
Whitehead, P.3
Ryan, K.4
Burkley, M.5
McMahon, W.6
|